Furthermore, tetrahydrohyperforin was shown to reduce the cholinergic markers associated with Aβ plaques and Aβ accumulation, as well as decreasing tau phosphorylation, in AD-mouse models [317,318]. Here, MAPT is linked to Alzheimer disease.